优思灵30R治疗2型糖尿病的疗效及安全性观察(1)
[摘要] 目的 观察优思灵30R治疗2型糖尿病的疗效及安全性。方法 选取2018年1—7月该院2型糖尿病患者92例，在采用医学营养治疗、运动疗法的基础上，随机分为观察组(46例)和对照组(46例)。对照组给予诺和灵30R治疗，观察组给予优思灵30R治疗，两组患者疗程12周。观察两组患者空腹血糖(FBG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPBG)、临床总有效率情况及不良反应情况。 结果 治疗12周后，两组患者FBG、HbA1c、2 hPBG较治疗前均明显下降，差异有统计学意义(P<0.05)，两组间对比差异无统计学意义(P>0.05)，两组患者临床总有效率、低血糖发生率之间比较差异无统计学意义(P>0.05)。结论 优思灵30R治疗2型糖尿病能显著降低FBG、HbA1c、2hPBG，临床疗效及治疗安全性不劣于诺和灵30R，值得临床推广。
[关键词] 优思灵30R;2型糖尿病;疗效;安全性
[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062(2018)09(b)-0076-02
Efficacy and Safety of Yousiling 30R in the Treatment of Type 2 Diabetes
LI Na， DAI Chao
Department of Internal Medicine， Section One， Hanzhong Second People's Hospital， Hanzhong， Shanxi Province， 723000 China
[Abstract] Objective To observe the efficacy and safety of Yousiling 30R in the treatment of type 2 diabetes mellitus. Methods From January to July 2018， Ninety-two patients with type 2 diabetes were randomly divided into observation group (46 cases) and control group (46 cases) on the basis of medical nutrition therapy and exercise therapy. The control group was treated with Nuoheling 30R， the observation group was given Yusiling 30R， and the two groups were treated for 12 weeks. Fasting blood glucose (FBG)， glycosylated hemoglobin (HbA1c)， postprandial 2-hour blood glucose (2 hPBG)， clinical total effective rate and adverse reactions were observed. Results After 12 weeks of treatment， the FBG， HbA1c and 2 hPBG of the two groups were significantly lower than those before treatment， and the difference was statistically significant (P<0.05). There was no significant difference between the two groups (P>0.05). There was no significant difference in the clinical total effective rate and the incidence of hypoglycemia between the two groups (P>0.05). Conclusion Yousiling 30R can significantly reduce FBG， HbA1c and 2 hPBG in the treatment of type 2 diabetes. The clinical efficacy and safety of treatment are not inferior to Nuoheling 30R， which is worthy of clinical promotion.
[Key words] Yousiling 30R; Type 2 diabetes; Efficacy; Safety
2型糖尿病(Type 2 Diabetes，T2DM)是在多種致病因素共同作用下致使血液平衡受到破坏，引起胰岛素分泌不足，从而导致血糖升高，部分患者伴有胰岛素分泌障碍，需要补充外源性胰岛素才能维持血糖在安全水平[1]。优思灵30R注射液是国产的重组人胰岛素生物制剂，旨在观察优思灵30R治疗T2DM的疗效及安全性，对该院2018年1—7月收治的92例T2DM患者进行了观察和分析，现报道如下。
1 资料与方法
1.1 一般资料
选取该科收治的T2DM患者92例，将患者随机分为观察组(46例)和对照组(46例)。观察组中，男性23例，女性23例，年龄48～62岁，平均年龄(56.83±5.87)岁;对照组中，男性24例，女性22例，年龄47～63岁，平均年龄(57.04±6.02)岁。严格排除有药物相关禁忌证、入组前已采用胰岛素治疗及其他口服降糖药物治疗、Ⅰ型糖尿病、肥胖、高血压、心脑血管疾病、感染性疾病、急慢性胰腺炎、恶性肿瘤、肝肾功能不全、其他内分泌代谢性疾病、妊娠、哺乳期等患者。两组性别、年龄等一般资料比较差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(李娜 代超)
[关键词] 优思灵30R;2型糖尿病;疗效;安全性
[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062(2018)09(b)-0076-02
Efficacy and Safety of Yousiling 30R in the Treatment of Type 2 Diabetes
LI Na， DAI Chao
Department of Internal Medicine， Section One， Hanzhong Second People's Hospital， Hanzhong， Shanxi Province， 723000 China
[Abstract] Objective To observe the efficacy and safety of Yousiling 30R in the treatment of type 2 diabetes mellitus. Methods From January to July 2018， Ninety-two patients with type 2 diabetes were randomly divided into observation group (46 cases) and control group (46 cases) on the basis of medical nutrition therapy and exercise therapy. The control group was treated with Nuoheling 30R， the observation group was given Yusiling 30R， and the two groups were treated for 12 weeks. Fasting blood glucose (FBG)， glycosylated hemoglobin (HbA1c)， postprandial 2-hour blood glucose (2 hPBG)， clinical total effective rate and adverse reactions were observed. Results After 12 weeks of treatment， the FBG， HbA1c and 2 hPBG of the two groups were significantly lower than those before treatment， and the difference was statistically significant (P<0.05). There was no significant difference between the two groups (P>0.05). There was no significant difference in the clinical total effective rate and the incidence of hypoglycemia between the two groups (P>0.05). Conclusion Yousiling 30R can significantly reduce FBG， HbA1c and 2 hPBG in the treatment of type 2 diabetes. The clinical efficacy and safety of treatment are not inferior to Nuoheling 30R， which is worthy of clinical promotion.
[Key words] Yousiling 30R; Type 2 diabetes; Efficacy; Safety
2型糖尿病(Type 2 Diabetes，T2DM)是在多種致病因素共同作用下致使血液平衡受到破坏，引起胰岛素分泌不足，从而导致血糖升高，部分患者伴有胰岛素分泌障碍，需要补充外源性胰岛素才能维持血糖在安全水平[1]。优思灵30R注射液是国产的重组人胰岛素生物制剂，旨在观察优思灵30R治疗T2DM的疗效及安全性，对该院2018年1—7月收治的92例T2DM患者进行了观察和分析，现报道如下。
1 资料与方法
1.1 一般资料
选取该科收治的T2DM患者92例，将患者随机分为观察组(46例)和对照组(46例)。观察组中，男性23例，女性23例，年龄48～62岁，平均年龄(56.83±5.87)岁;对照组中，男性24例，女性22例，年龄47～63岁，平均年龄(57.04±6.02)岁。严格排除有药物相关禁忌证、入组前已采用胰岛素治疗及其他口服降糖药物治疗、Ⅰ型糖尿病、肥胖、高血压、心脑血管疾病、感染性疾病、急慢性胰腺炎、恶性肿瘤、肝肾功能不全、其他内分泌代谢性疾病、妊娠、哺乳期等患者。两组性别、年龄等一般资料比较差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(李娜 代超)